RCEL Avita Medical Limited

Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine. It operates through the following segments: Asia Pacific, EMEA (Europe, Middle East and Africa), and Americas. The Asia Pacific and EMEA segments involves in selling recell devices. The America segment offers recell devices to compassionate use cases at hospitals that is paid by Biomedical Advanced Research and Development Authority. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:AVH.

$14.10  -0.71 (-4.79%)
As of 11/26/2021 13:00:01 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  Australia
Country of incorporation:  USA
IPO date:  03/29/2012
Outstanding shares:  24,925,118
Average volume:  113,164
Market cap:   $369,140,998
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    05380C102
ISIN:        US05380C1027
Sedol:      BMX0JN6
Valuation   (See tab for details)
PE ratio:   -15.76
PB ratio:   15.75
PS ratio:   11.83
Return on equity:   -20.01%
Net income %:   -71.51%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy